<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7438404\results\search\drug\results.xml">
  <result pre="nM HCoV-NL63 Replication 0.08â€&quot;0.3 Î¼M SARS-CoV-2 Replication 0.024 Î¼M MERS-CoV" exact="Ribavirin" post="Replication 20 Î¼g mLâ€&quot;1 SARS-CoV Synthetic molecule, highly tolerated,"/>
  <result pre="al., 2005; Barnard et al., 2006 Acyclic sugar scaffold of" exact="acyclovir" post="Replication 23 Î¼M MERS-CoV Synthetic molecule, highly tolerated, easily"/>
  <result pre="Acyclovir, easily produced, but there are no in vivo assays" exact="Niclosamide" post="Replication 0.1 Î¼M SARS-CoV Drug already in use to"/>
  <result pre="people, and the drug has some adverse effects. Lopinavir and" exact="Ritonavir" post="Inhibited SARS-CoV and MERS-CoV Replication (protease inhibitor) NE Clinical"/>
  <result pre="storms, improving antiviral response, and providing the best clinical outcomes." exact="Chloroquine" post="Inhibited HIV, CHIKV, SARS-CoV, and SARS-CoV-2 Entry Improved outcomes"/>
  <result pre="are being conducted Impairs virus replication and has anti-inflammatory activities" exact="Chloroquine" post="possesses important side effects and is indicated only in"/>
  <result pre="trials are being conducted Less toxic option, impairs virus replication" exact="Hydroxychloroquine" post="improved patientsâ€™ outcomes, including when associated with azithromycin. Less"/>
  <result pre="outcomes, including when associated with azithromycin. Less toxic option than" exact="chloroquine" post="treatment, but there are studies with contrasting results regarding"/>
  <result pre="nM and CC50 of 80 Î¼M (Pyrc et al., 2006)." exact="Ribavirin" post="is a synthetic nucleoside analog of guanosine used for"/>
  <result pre="hepatitis C virus (HCV) (PubChem, 2005c). The antiviral activities of" exact="ribavirin" post="against several RNA viruses have been described, and it"/>
  <result pre="mice (Barnard et al., 2006). The in vitro decrease of" exact="ribavirin" post="efficacy was demonstrated to be associated with the excision"/>
  <result pre="by conserved coronavirus proofreading mechanisms (Ferron et al., 2017). Moreover," exact="ribavirin" post="showed good results for the treatment of critical MERS-CoV"/>
  <result pre="patients (Al-Tawfiq et al., 2014), and the combined treatment of" exact="ribavirin" post="with type I Interferons (IFN-I) in primate models improved"/>
  <result pre="models improved MERS disease symptoms (Falzarano et al., 2013b). Although" exact="ribavirin" post="has been given as part of treatment regimens for"/>
  <result pre="a nucleoside analog based on the acyclic sugar scaffold of" exact="acyclovir" post="showed antiviral potential against coronaviruses (Tan et al., 2004)."/>
  <result pre="of Niclosamide, a drug used in antihelminthic treatment (Katz, 1977)." exact="Niclosamide" post="presented antiviral activity on post-entry steps of SARS-CoV infection"/>
  <result pre="E6 cells (Wen et al., 2007). Both authors suggested that" exact="Niclosamide" post="impairs post-entry steps. However, this effect seems to not"/>
  <result pre="to an interaction with 3CLpro. An additional potential compound is" exact="mycophenolic acid" post="(MPA), an antibiotic derived from penicillium fungal species (PubChem,"/>
  <result pre="hand, are a class of adamantane-based compounds conjugated with a" exact="pyridoxal" post="moiety (vitamin B6) (Kesel, 2003). These molecules showed effective"/>
  <result pre="al., 2011, 2013; Pfefferle et al., 2011). Alisporivir, a non-immunosuppressive" exact="cyclosporin A" post="analog, inhibited the replication of SARS-CoV in Vero E6"/>
  <result pre="assays (de Wilde et al., 2014; Kim et al., 2015)." exact="Ritonavir" post="also demonstrated anti-MERS-CoV activities with an EC50 of 24.9"/>
  <result pre="In clinical assays for MERS-CoV, the association of Lopinavir with" exact="Ritonavir" post="reduced adverse clinical outcomes and viral load in infected"/>
  <result pre="Yao et al., 2020a). In particular, for SARS-CoV, Lopinavir and" exact="Ritonavir" post="presented a low to medium antiviral activity in vitro,"/>
  <result pre="performed yet (Yao et al., 2020a). In addition, Lopinavir and" exact="Ritonavir" post="played an important role in the clinical outcome of"/>
  <result pre="The authors proposed that the low efficacy of Lopinavir with" exact="Ritonavir" post="might be associated with the time of administration, since"/>
  <result pre="al., 2020b). Later, it was shown that the association of" exact="lopinavir" post="and ritonavir with interferon-Î²1 and ribavirin to treat mild"/>
  <result pre="Later, it was shown that the association of lopinavir and" exact="ritonavir" post="with interferon-Î²1 and ribavirin to treat mild to moderate"/>
  <result pre="that the association of lopinavir and ritonavir with interferon-Î²1 and" exact="ribavirin" post="to treat mild to moderate COVID-19 patients alleviated symptoms"/>
  <result pre="(Kobayashi et al., 1993). There are two subtypes of IFN-I," exact="alpha" post="(IFN-Î±) and beta (IFN-Î²) (Samuel, 2001). IFN-Î² is associated"/>
  <result pre="in clinical trials, improving outcomes in COVID-19 patients as in" exact="lopinavir" post="or ribavirin (Hung et al., 2020). COVID-19 patients with"/>
  <result pre="trials, improving outcomes in COVID-19 patients as in lopinavir or" exact="ribavirin" post="(Hung et al., 2020). COVID-19 patients with mild to"/>
  <result pre="improve symptoms in COVID-19 patients (Zha et al., 2020). Moreover," exact="dexamethasone" post="emerged as a potential drug for treating COVID-19 patients,"/>
  <result pre="controlled, open-lab, and multicenter trial that assessed the effects of" exact="dexamethasone" post="in 454 patients, described to date in pre-print findings"/>
  <result pre="in pre-print findings (Horby et al., 2020). Data suggested that" exact="dexamethasone" post="reduced death in one-third of patients in invasive mechanical"/>
  <result pre="considering the preliminary results, the WHO suggested that treatment with" exact="dexamethasone" post="may be applied during the third phase of COVID-19,"/>
  <result pre="and associated with significant clinical improvement (Toniati et al., 2020)." exact="Chloroquine" post="is a 9-aminoquinole that increases the pH in acidic"/>
  <result pre="HIV and other viruses (Jacobson et al., 2016; Al-Bari, 2017)." exact="Chloroquine" post="was described as an entry inhibitor of SARS-CoV infection"/>
  <result pre="an in vivo study in cats demonstrated that treatment with" exact="chloroquine" post="improved the clinical score of treated groups when compared"/>
  <result pre="when compared to the untreated group (Takano et al., 2013)." exact="Chloroquine" post="also had its anti-CoV activities tested in Vero cells"/>
  <result pre="al., 2020b; Yao et al., 2020b). Despite the performance of" exact="chloroquine" post="in vitro, clinical studies conducted in China and France"/>
  <result pre="2020; Molina et al., 2020). Gao and collaborators indicated that" exact="chloroquine" post="phosphate was recommended to treat COVID-19-associated pneumonia only during"/>
  <result pre="of its antiviral and anti-inflammatory activities (Gao et al., 2020)." exact="Hydroxychloroquine" post="is an analog of chloroquine that was described as"/>
  <result pre="activities (Gao et al., 2020). Hydroxychloroquine is an analog of" exact="chloroquine" post="that was described as having antiviral activity, inhibiting SARS-CoV-2"/>
  <result pre="an open-label non-randomized study by Gautret and colleagues affirmed that" exact="hydroxychloroquine" post="reduced symptoms from SARS-CoV-2 patients and that association with"/>
  <result pre="hydroxychloroquine reduced symptoms from SARS-CoV-2 patients and that association with" exact="azithromycin" post="could reinforce its effects (Gautret et al., 2020). However,"/>
  <result pre="(Juurlink, 2020). Recent studies have been contradicting the safety of" exact="chloroquine" post="and hydroxychloroquine use, as these drugs presented severe side"/>
  <result pre="Recent studies have been contradicting the safety of chloroquine and" exact="hydroxychloroquine" post="use, as these drugs presented severe side effects that"/>
  <result pre="an effect that may be enhanced by concomitant use of" exact="azithromycin" post="(Chorin et al., 2020). Both chloroquine and hydroxychloroquine interfere"/>
  <result pre="by concomitant use of azithromycin (Chorin et al., 2020). Both" exact="chloroquine" post="and hydroxychloroquine interfere with ventricular repolarization, leading to prolongation"/>
  <result pre="use of azithromycin (Chorin et al., 2020). Both chloroquine and" exact="hydroxychloroquine" post="interfere with ventricular repolarization, leading to prolongation of the"/>
  <result pre="polymorphisms of hepatic cytochrome P450 enzyme 2D6 (CYP2D6), responsible for" exact="chloroquine" post="metabolization) (Kirchheiner et al., 2008; Lee et al., 2016)."/>
  <result pre="for the treatment (Smith, 2020). Recently, the WHO stopped the" exact="hydroxychloroquine" post="arm of the Solidarity trial to treat COVID-19 based"/>
  <result pre="2020c). Besides, the FDA also cautioned against the administration of" exact="hydroxychloroquine" post="or chloroquine in COVID-19 patients, mainly due to the"/>
  <result pre="the FDA also cautioned against the administration of hydroxychloroquine or" exact="chloroquine" post="in COVID-19 patients, mainly due to the risk of"/>
  <result pre="survival of animals. In addition, Saracatinib, Tizoxanide, Nitazoxanide, Niclosamide, and" exact="Ribavirin" post="are molecules licensed to treat diseases such as those"/>
  <result pre="not reduce symptoms and/or decrease viral load. Tocilizumab, Chloroquine, and" exact="Hydroxychloroquine" post="have been demonstrated to inhibit SARS-CoV-2 in vitro and,"/>
  <result pre="viral load in patients despite the strong adverse effects of" exact="Chloroquine" post="(Table 2). Even so, recent studies are contradicting the"/>
  <result pre="Even so, recent studies are contradicting the safety profiles of" exact="Chloroquine" post="and Hydroxychloroquine, since they might cause arrhythmia in patients,"/>
  <result pre="2020). In addition, previous studies demonstrated that the use of" exact="Chloroquine" post="analogs for decades against malaria has established chloroquine-resistant Plasmodium"/>
  <result pre="However, there is a possibility that prophylactic exposure to pro-apoptotic" exact="chloroquine" post="drugs caused natural selection for strains of viruses and"/>
  <result pre="C.MurceE.CortopassiW. A.PimentelA. S.AlmeidaM. M. F. S.BarrosD. C. S.et al. (2018)." exact="Chloroquine" post="analogs as antimalarial candidates with potent in vitro and"/>
  <result pre="print. 10.1002/jmv.2596432369191 Al-BariM. A. A. (2017). Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
  <result pre="emerging viral diseases.Pharmacol. Res. Perspect.51â€&quot;13. 10.1002/prp2.29328596841 Al-TawfiqJ. A.MomattinH.DibJ.MemishZ. A. (2014)." exact="Ribavirin" post="and interferon therapy in patients infected with the Middle"/>
  <result pre="10.3390/v406101122816037 CalyL.DruceJ. D.CattonM. G.JansD. A.WagstaffK. M. (2020). The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro.Antiviral Res.178:104787. 10.1016/j.antiviral.2020.10478732251768"/>
  <result pre="Med. Virol.92418â€&quot;423. 10.1002/jmv.2568131967327 ChenJ.LiuD.LiuL.LiuP.XuQ.XiaL.et al. (2020). [A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with moderate COVID-19].Zhejiang Xue Xue"/>
  <result pre="Overview.Curr. Trop. Med. Rep.31â€&quot;4. 10.1007/s40475-020-00201-632219057 ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.et al. (2020). Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
  <result pre="induces severe in vitro cytopathology and is strongly inhibited by" exact="cyclosporin A" post="or interferon-Î± treatment.J. Gen. Virol.941749â€&quot;1760. 10.1099/vir.0.052910-023620378 de WildeA. H.Zevenhoven-DobbeJ."/>
  <result pre="FalzaranoD.de WitE.RasmussenA. L.FeldmannF.OkumuraA.ScottD. P.et al. (2013b). Treatment with interferon-Î±2b and" exact="ribavirin" post="improves outcome in MERS-CoVâ€&quot;infected rhesus macaques.Nat. Med.191313â€&quot;1317. 10.1038/nm.336224013700 collab:"/>
  <result pre="Med.191313â€&quot;1317. 10.1038/nm.336224013700 collab: FDA (2020). FDA Cautions Against use of" exact="Hydroxychloroquine" post="or Chloroquine for COVID-19 Outside of the Hospital Setting"/>
  <result pre="collab: FDA (2020). FDA Cautions Against use of Hydroxychloroquine or" exact="Chloroquine" post="for COVID-19 Outside of the Hospital Setting or a"/>
  <result pre="al. (2017). Structural and molecular basis of mismatch correction and" exact="ribavirin" post="excision from coronavirus RNA.Proc. Natl. Acad. Sci. U S.A.115E162â€&quot;E171."/>
  <result pre="P. (Cambridge, MA: Academic Press), 1â€&quot;42. 10.1016/B978-0-12-815422-9.00001-2 GaoJ.TianZ.YangX. (2020). Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  <result pre="Ebola virus infection.Transfus. Apher. Sci.5631â€&quot;34. 10.1016/j.transci.2016.12.01428094110 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020)." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
  <result pre="infection.Transfus. Apher. Sci.5631â€&quot;34. 10.1016/j.transci.2016.12.01428094110 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020). Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="GirijalaR. L.SiddiqiI.KwakY.WrightD.PatelD. B.GoldbergL. H. (2019). Pustular DRESS syndrome secondary to" exact="hydroxychloroquine" post="with EBV reactivation.J. Drugs Dermatol. JDD18207â€&quot;209.30811149 GorbalenyaA. E.BakerS. C.BaricR."/>
  <result pre="entry.J. Virol.8112029â€&quot;12039. 10.1128/JVI.00315-0717715238 HartB. J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR. F.et al. (2014). Interferon-Î² and" exact="mycophenolic acid" post="are potent inhibitors of middle east respiratory syndrome coronavirus"/>
  <result pre="Engl. J. Med.382929â€&quot;936. 10.1056/NEJMoa200119132004427 HorbyP.LimW. S.EmbersonJ.MafhamM.BellJ.LinsellL.et al. (2020). Effect of" exact="dexamethasone" post="in hospitalized patients with COVID-19: preliminary report.medRxiv [Preprint]10.1101/2020.06.22.20137273 HsuL."/>
  <result pre="W.-H.ChuM.-Y.et al. (2020). Triple combination of interferon beta-1b, lopinavir-ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
  <result pre="JacobsonJ. M.BosingerS. E.KangM.Belaunzaran-ZamudioP.MatiningR. M.WilsonC. C.et al. (2016). The effect of" exact="chloroquine" post="on immune activation and interferon signatures associated with HIV-1.AIDS"/>
  <result pre="Agents Chemother.64e00819â€&quot;e00820. 10.1128/AAC.00819-2032366720 JuurlinkD. N. (2020). Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infection.CMAJ192E450â€&quot;E453. 10.1503/cmaj.20052832269021"/>
  <result pre="10.1128/AAC.00819-2032366720 JuurlinkD. N. (2020). Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infection.CMAJ192E450â€&quot;E453. 10.1503/cmaj.20052832269021 KaepplerU.StieflN.SchillerM.VicikR.BreuningA.SchmitzW.et al."/>
  <result pre="protease.Antiviral Res.97161â€&quot;168. 10.1016/j.antiviral.2012.11.00523219425 KimU. J.WonE.-J.KeeS.-J.JungS.-I.JangH.-C. (2015). Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndrome: a case"/>
  <result pre="(2016). Association of polymorphisms of cytochrome P450 2D6 with blood" exact="hydroxychloroquine" post="levels in patients with systemic lupus erythematosus.Arthritis Rheumatol.68184â€&quot;190. 10.1002/art.3940226316040"/>
  <result pre="TMPRSS2-expressing cells.Proc. Natl. Acad. Sci. U.S.A.1177001â€&quot;7003. 10.1073/pnas.200258911732165541 MautheM.OrhonI.RocchiC.ZhouX.LuhrM.HijlkemaK.-J.et al. (2018)." exact="Chloroquine" post="inhibits autophagic flux by decreasing autophagosome-lysosome fusion.Autophagy141435â€&quot;1455. 10.1080/15548627.2018.147431429940786 McDonaghP.SheehyP."/>
  <result pre="lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.AIDS231679â€&quot;1688. 10.1097/QAD.0b013e32832d735019487905 MohanD.MohandasE.RajatR. (1981)." exact="Chloroquine" post="psychosis: a chemical psychosis?J. Natl. Med. Assoc.731073â€&quot;1076.7310924 MolinaJ. M.DelaugerreC.Le"/>
  <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection.Med. Mal."/>
  <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection.Med. Mal. Infect.50:384. 10.1016/j.medmal.2020.03.00632240719"/>
  <result pre="Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and" exact="chloroquine" post="in healthy volunteers.PLoS Clin. Trials2:e6. 10.1371/journal.pctr.002000617213921 collab: National Research"/>
  <result pre="10.1016/j.bbrc.2003.12.08114715271 PreobrazhenskayaM. N.OlsufyevaE. N. (2004). Patents on glycopeptides of the" exact="vancomycin" post="family and their derivatives as antimicrobials: January 1999 â€&quot;"/>
  <result pre="MA: Springer), 597â€&quot;600. 10.1007/978-0-387-33012-9_108 RoquesP.ThibervilleS.-D.Dupuis-MaguiragaL.LumF.-M.LabadieK.MartinonF.et al. (2018). Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infection.Viruses10:268. 10.3390/v1005026829772762 RossignolJ.-F. (2014)."/>
  <result pre="Dis.6920â€&quot;28. 10.1136/ard.2008.10176619103632 SaijoM.MorikawaS.FukushiS.MizutaniT.HasegawaH.NagataN.et al. (2005). Inhibitory effect of mizoribine and" exact="ribavirin" post="on the replication of severe acute respiratory syndrome (SARS)-associated"/>
  <result pre="A.RaynesK. J.BrayP. G.ParkB. K.Oâ€™NeillP. M.WardS. A. (2002). Novel short chain" exact="chloroquine" post="analogues retain activity against chloroquine resistant K1 plasmodium falciparum.J."/>
  <result pre="A. (2002). Novel short chain chloroquine analogues retain activity against" exact="chloroquine" post="resistant K1 plasmodium falciparum.J. Med. Chem.454975â€&quot;4983. 10.1021/jm010870712408708 StruckA.-W.AxmannM.PfefferleS.DrostenC.MeyerB. (2012)."/>
  <result pre="inhibitor and vaccine.Cell. Mol. Immunol.17613â€&quot;620. 10.1038/s41423-020-0400-432203189 TakanoT.KatohY.DokiT.HohdatsuT. (2013). Effect of" exact="chloroquine" post="on feline infectious peritonitis virus infection in vitro and"/>
  <result pre="herpes simplex virus proliferation.Oncotarget103209â€&quot;3226. 10.18632/oncotarget.2690731143369 UnÃ¼bolM.AyhanM.GuneyE. (2011). Hypoglycemia induced by" exact="hydroxychloroquine" post="in a patient treated for rheumatoid arthritis.J. Clin. Rheumatol."/>
  <result pre="Pract. Rep. Rheum. Musculoskelet. Dis.1746â€&quot;47. 10.1097/RHU.0b013e3182098e1f21169846 UrsingJ.RomboL.EksborgS.LarsonL.BruvollA.TarningJ.et al. (2020). High-dose" exact="chloroquine" post="for uncomplicated plasmodium falciparum malaria is well tolerated and"/>
  <result pre="well tolerated and causes similar QT interval prolongation as standard-dose" exact="chloroquine" post="in children.Antimicrob. Agents Chemother.64:e01846-19. 10.1128/AAC.01846-1931907183 van DoremalenN.BushmakerT.MorrisD. H.HolbrookM. G.GambleA.WilliamsonB."/>
  <result pre="10.1056/NEJMc200497332182409 VargheseF. S.KaukinenP.GlÃ¤skerS.BespalovM.HanskiL.WennerbergK.et al. (2016). Discovery of berberine, abamectin and" exact="ivermectin" post="as antivirals against chikungunya and other alphaviruses.Antiviral Res.126117â€&quot;124. 10.1016/j.antiviral.2015.12.01226752081"/>
  <result pre="dengue viruses.Bioinformation8519â€&quot;522. 10.6026/9732063000851922829722 VincentM. J.BergeronE.BenjannetS.EricksonB. R.RollinP. E.KsiazekT. G.et al. (2005)." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
  <result pre="blocking SARS-CoV-2 infection.Nat. Commun.11:2251. 10.1038/s41467-020-16256-y32366817 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.et al. (2020b). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports(accessed July 04, 2020) collab: WHO (2020c). Q&amp;amp;A:" exact="Hydroxychloroquine" post="and COVID-19. Available online at: https://www.who.int/news-room/q-a-detail/q-a-hydroxychloroquine-and-covid-19(accessed July 5, 2020)"/>
  <result pre="5â€™ ends.Virus Res.206120â€&quot;133. 10.1016/j.virusres.2015.02.02525736566 YaoT.-T.QianJ.-D.ZhuW.-Y.WangY.WangG.-Q. (2020a). A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirusâ€&quot;A possible reference"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 </snippets>
</snippetsTree>
